<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03754218</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00054157</org_study_id>
    <nct_id>NCT03754218</nct_id>
  </id_info>
  <brief_title>Amnion Wound Covering for Enhanced Wound Healing</brief_title>
  <official_title>Phase 1 Study of Human Amnion Membrane Powder for Enhanced Wound Healing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to find our if human amnion membrane powder can be
      safely used as a covering for wounds and can improve the condition of skin graft donor sites.
      The amnion powder product is composed of &quot;lyophilized&quot; (freeze-dried), &quot;gamma irradiation
      sterilized&quot; (exposed to bacteria killing radiation) fragments of amniotic membrane.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extensive burns and full thickness skin wounds can be devastating to patients, even when
      treated with our current standard of care. There are an estimated 500,000 burns treated in
      the United States each year. Moreover, in the military environment, soldiers who suffer from
      extensive burn injuries on the battlefield may benefit from rapid treatments that result in
      complete closure and protection of the wounds. As such, there is a need for mobile platform
      technologies that allow fast treatment at the site where the injury occurred, or at the very
      least at the forward operating sites. This safety investigation of a human amnion membrane
      powder product for wound healing is a with-in patient-controlled study, enrolling 10 subjects
      undergoing donor skin graft harvest. The single-center study will include patients undergoing
      donor skin harvest such that two regions, of at least 25 cm2 and separated by at least a 5 cm
      gap, of donor site wounds in comparable skin locations, are available for covering with the
      amnion membrane product and the current institutional standard of care (SOC) covering. The
      proposed sterilized product is composed of lyophilized, gamma-irradiated powder made from
      amniotic membrane for topical application with the purpose of enhanced wound healing.

      The primary objective of the study is to evaluate the safety of a human amnion membrane
      product intended for enhanced wound healing. The secondary objective is efficacy as evidenced
      by complete wound closure relative to standard of care (SOC) treatment in a similar wound on
      the same subject at donor sites created for skin grafts at 14 days and 28 days
      postoperatively.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Donor Site Wound Closure</measure>
    <time_frame>Week 4</time_frame>
    <description>Wound closure for both amnion membrane product and SOC will be defined as skin re-epithelization without drainage or dressing requirements confirmed at two consecutive study visits 2 weeks apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Donor Site Wound Healing</measure>
    <time_frame>week 12</time_frame>
    <description>Wound Healing for both amnion membrane product and SOC will be assessed clinically confirmed at two consecutive study visits 2 weeks apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of infection</measure>
    <time_frame>up to 26 Weeks</time_frame>
    <description>The presence of infection will be evaluated in accordance with guidelines derived from Cutting and Harding using standard clinical measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vancouver Scar Assessment Scale</measure>
    <time_frame>up to 26 Weeks</time_frame>
    <description>Scar formation will be evaluated the Vancouver Scar Assessment Scale.The scale is composed by the following Sub scales (minimum and maximum ranges in parenthesis): Pigmentation (0-2), Vascularity (0-3), Pliability (0-5), Height (0-3). Total score 0-13. Lower score denotes better outcomes for total range and subscales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Dermatitis</measure>
    <time_frame>Up to 26 Weeks</time_frame>
    <description>Allergic Response to Human Amnion Membrane Product Covering will be assessed clinically by the presence of dermatitis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Burns</condition>
  <condition>Wound of Skin</condition>
  <condition>Skin Wound</condition>
  <arm_group>
    <arm_group_label>Amnion membrane product treatment area</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The prepared amnion membrane powder will be directly applied to the prepared donor wound site (Site A). The wound will then be covered with the SOC dressing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC Wound Covering treatment area</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The donor wound site (Site B) will be covered per SOC (Standard of care).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amnion Membrane Powder</intervention_name>
    <description>This sterilized product is composed of lyophilized, gamma-irradiated powder made from amniotic membrane for topical application with the purpose of enhanced wound healing.</description>
    <arm_group_label>Amnion membrane product treatment area</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SOC Wound Covering</intervention_name>
    <description>Institutional standard of care wound covering.</description>
    <arm_group_label>Amnion membrane product treatment area</arm_group_label>
    <arm_group_label>SOC Wound Covering treatment area</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject requires autologous primary skin graft with two donor sites in similar
             areas, each measuring at least 25 cm2 with the likely depth of 0.012 inches and
             separated by a 5 cm gap. It is preferable that the two sites be on right and left
             sides of the body, but it is not an exclusion if they must be on the same side.

          -  Eligible primary wound sites may be traumatic or chronic, and will be at least 50 cm2
             (that will receive the donor graft) to allow assessment of two separate experimental
             donor sites of 25 cm2.

          -  The subject is between the ages of 18 and 85 years of age.

          -  The subject is willing to complete all follow-up evaluations required by the study
             protocol.

          -  The subject is to abstain from any other covering or treatment of the wound(s) for the
             duration of the study unless medically necessary.

          -  The subject agrees to abstain from enrollment in any other interventional clinical
             trial for the duration of the study.

          -  The subject and/or guardian is able to read and understand instructions and give
             informed, voluntary, written consent.

          -  The subject is able and willing to follow the protocol requirements

        Exclusion Criteria:

          -  The subject's primary wound site is less than 50 cm2The subject's primary wound site
             is not deemed appropriate for skin graft based upon the investigator's clinical
             experience

          -  The subject has a microbiologically proven pre-existing local or systemic bacterial
             infection.

          -  The subject has been receiving a systemic antibiotic for more than 48 hours prior to
             grafting.

          -  Unstable cardiac disorders within the past 6 months including angina, abnormal ECG,
             history of cardiac arrest, surgery and/or other interventional procedure.

          -  Hepatic disease or altered liver function as defined by ALT or AST value &gt;3 times the
             upper limit of normal and/or T. Bilirubin &gt;1.5 mg/dL at screening

          -  Renal disease or altered renal function as defined by serum creatinine &gt; 2 mg/dL at
             screening, or end-stage renal disease.

          -  Hemoglobin &lt;10.0 or &gt;19.0 g/dL

          -  Known coagulopathy or platelet disorder, or INR &gt; 1.6 , PTT &gt; 38 sec; PLT &lt; 50,000 at
             screening

          -  The subject is known to have a pre-existing, chronic condition that, in the opinion of
             the Investigator, may interfere with wound healing including but not limited to:
             current malignancy, uncontrolled diabetes (HbA1c &gt;8) or diabetic ulcers, autoimmune
             disease or other immunocompromised diseases, renal impairment or ESRD, liver disease,
             hematological
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Molnar, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lesher AP, Curry RH, Evans J, Smith VA, Fitzgerald MT, Cina RA, Streck CJ, Hebra AV. Effectiveness of Biobrane for treatment of partial-thickness burns in children. J Pediatr Surg. 2011 Sep;46(9):1759-63. doi: 10.1016/j.jpedsurg.2011.03.070.</citation>
    <PMID>21929986</PMID>
  </reference>
  <reference>
    <citation>Rahmanian-Schwarz A, Beiderwieden A, Willkomm LM, Amr A, Schaller HE, Lotter O. A clinical evaluation of Biobrane(®) and Suprathel(®) in acute burns and reconstructive surgery. Burns. 2011 Dec;37(8):1343-8. doi: 10.1016/j.burns.2011.07.010. Epub 2011 Aug 17.</citation>
    <PMID>21852044</PMID>
  </reference>
  <reference>
    <citation>PIGEON J. Treatment of second-degree burns with amniotic membranes. Can Med Assoc J. 1960 Oct 15;83:844-5.</citation>
    <PMID>13735672</PMID>
  </reference>
  <reference>
    <citation>Faulk WP, Matthews R, Stevens PJ, Bennett JP, Burgos H, Hsi BL. Human amnion as an adjunct in wound healing. Lancet. 1980 May 31;1(8179):1156-8.</citation>
    <PMID>6155575</PMID>
  </reference>
  <reference>
    <citation>Bose B. Burn wound dressing with human amniotic membrane. Ann R Coll Surg Engl. 1979 Nov;61(6):444-7.</citation>
    <PMID>496235</PMID>
  </reference>
  <reference>
    <citation>Koob TJ, Rennert R, Zabek N, Massee M, Lim JJ, Temenoff JS, Li WW, Gurtner G. Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing. Int Wound J. 2013 Oct;10(5):493-500. doi: 10.1111/iwj.12140. Epub 2013 Aug 1.</citation>
    <PMID>23902526</PMID>
  </reference>
  <reference>
    <citation>Sawhney CP. Amniotic membrane as a biological dressing in the management of burns. Burns. 1989 Oct;15(5):339-42.</citation>
    <PMID>2590408</PMID>
  </reference>
  <reference>
    <citation>C. Ho, K. Tran, M. Hux, G. Sibbald, K. Campbell, Artificial skin grafts in chronic wound care: A meta-analysis of clinical efficacy and a review of cost-effectiveness, (2005).</citation>
  </reference>
  <reference>
    <citation>Thapliyal, G.K., Kumar, V. and Gour, S., Amniotic Membrane: An Innovative Material for Repair and Regeneration in Oral and Maxillofacial region-A Review. Rama University Journal &amp; Dental Sciences, 3(2) (2016) 1-6.</citation>
  </reference>
  <reference>
    <citation>J.S. Davis, Skin transplantation, Johns Hopkins Hospital Reports 15 (1910) 307-96</citation>
  </reference>
  <reference>
    <citation>Pachigolla G, Prasher P, Di Pascuale MA, McCulley JP, McHenry JG, Mootha VV. Evaluation of the role of ProKera in the management of ocular surface and orbital disorders. Eye Contact Lens. 2009 Jul;35(4):172-5. doi: 10.1097/ICL.0b013e3181a66a12.</citation>
    <PMID>19474753</PMID>
  </reference>
  <reference>
    <citation>Honavar SG, Bansal AK, Sangwan VS, Rao GN. Amniotic membrane transplantation for ocular surface reconstruction in Stevens-Johnson syndrome. Ophthalmology. 2000 May;107(5):975-9.</citation>
    <PMID>10811093</PMID>
  </reference>
  <reference>
    <citation>Mohammadi AA, Seyed Jafari SM, Kiasat M, Tavakkolian AR, Imani MT, Ayaz M, Tolide-ie HR. Effect of fresh human amniotic membrane dressing on graft take in patients with chronic burn wounds compared with conventional methods. Burns. 2013 Mar;39(2):349-53. doi: 10.1016/j.burns.2012.07.010. Epub 2012 Aug 27.</citation>
    <PMID>22951345</PMID>
  </reference>
  <reference>
    <citation>Branski LK, Herndon DN, Celis MM, Norbury WB, Masters OE, Jeschke MG. Amnion in the treatment of pediatric partial-thickness facial burns. Burns. 2008 May;34(3):393-9. Epub 2007 Oct 24.</citation>
    <PMID>17920202</PMID>
  </reference>
  <reference>
    <citation>Ravishanker R, Bath AS, Roy R. &quot;Amnion Bank&quot;--the use of long term glycerol preserved amniotic membranes in the management of superficial and superficial partial thickness burns. Burns. 2003 Jun;29(4):369-74.</citation>
    <PMID>12781617</PMID>
  </reference>
  <reference>
    <citation>Hermans MH. Preservation methods of allografts and their (lack of) influence on clinical results in partial thickness burns. Burns. 2011 Aug;37(5):873-81. doi: 10.1016/j.burns.2011.01.007. Epub 2011 Feb 25. Review.</citation>
    <PMID>21353745</PMID>
  </reference>
  <reference>
    <citation>Fairbairn NG, Randolph MA, Redmond RW. The clinical applications of human amnion in plastic surgery. J Plast Reconstr Aesthet Surg. 2014 May;67(5):662-75. doi: 10.1016/j.bjps.2014.01.031. Epub 2014 Jan 31. Review.</citation>
    <PMID>24560801</PMID>
  </reference>
  <reference>
    <citation>Lo K, Kohanim S, Trief D, Chodosh J. Role of amniotic membrane transplantation in acute chemical injury. Int Ophthalmol Clin. 2013 Fall;53(4):33-41. doi: 10.1097/IIO.0b013e31829ceec8. Review.</citation>
    <PMID>24088931</PMID>
  </reference>
  <reference>
    <citation>Tseng SC, Prabhasawat P, Lee SH. Amniotic membrane transplantation for conjunctival surface reconstruction. Am J Ophthalmol. 1997 Dec;124(6):765-74.</citation>
    <PMID>9402822</PMID>
  </reference>
  <reference>
    <citation>Ganatra MA. Amniotic membrane in surgery. J Pak Med Assoc. 2003 Jan;53(1):29-32. Review.</citation>
    <PMID>12666850</PMID>
  </reference>
  <reference>
    <citation>Koziak A, Salagierski M, Marcheluk A, Szcześniewski R, Sosnowski M. Early experience in reconstruction of long ureteral strictures with allogenic amniotic membrane. Int J Urol. 2007 Jul;14(7):607-10.</citation>
    <PMID>17645603</PMID>
  </reference>
  <reference>
    <citation>Tao H, Fan H. Implantation of amniotic membrane to reduce postlaminectomy epidural adhesions. Eur Spine J. 2009 Aug;18(8):1202-12. doi: 10.1007/s00586-009-1013-x. Epub 2009 Apr 30.</citation>
    <PMID>19404691</PMID>
  </reference>
  <reference>
    <citation>Chou CT, Lee C, Hwang JL. Amniotic membrane used for vulvar adhesion treatment. Arch Gynecol Obstet. 2001 Nov;265(4):223-4.</citation>
    <PMID>11789753</PMID>
  </reference>
  <reference>
    <citation>Fetterolf DE, Snyder RJ. Scientific and clinical support for the use of dehydrated amniotic membrane in wound management. Wounds. 2012 Oct;24(10):299-307.</citation>
    <PMID>25876055</PMID>
  </reference>
  <reference>
    <citation>Zelen CM, Serena TE, Denoziere G, Fetterolf DE. A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers. Int Wound J. 2013 Oct;10(5):502-7. doi: 10.1111/iwj.12097. Epub 2013 Jun 7.</citation>
    <PMID>23742102</PMID>
  </reference>
  <reference>
    <citation>Zelen CM. An evaluation of dehydrated human amniotic membrane allografts in patients with DFUs. J Wound Care. 2013 Jul;22(7):347-8, 350-1.</citation>
    <PMID>24159656</PMID>
  </reference>
  <reference>
    <citation>C.M. Zelen, T.E. Serena, D.E. Fetterolf, Dehydrated human amnion/chorion membrane allografts in patients with chronic diabetic foot ulcers: a long-term follow-up study, Wound Medicine 4 (2014) 1-4</citation>
  </reference>
  <reference>
    <citation>Forbes J, Fetterolf DE. Dehydrated amniotic membrane allografts for the treatment of chronic wounds: a case series. J Wound Care. 2012 Jun;21(6):290, 292, 294-6.</citation>
    <PMID>22886294</PMID>
  </reference>
  <reference>
    <citation>Sheikh ES, Sheikh ES, Fetterolf DE. Use of dehydrated human amniotic membrane allografts to promote healing in patients with refractory non healing wounds. Int Wound J. 2014 Dec;11(6):711-7. doi: 10.1111/iwj.12035. Epub 2013 Feb 15.</citation>
    <PMID>23409746</PMID>
  </reference>
  <reference>
    <citation>Bujang-Safawi E, Halim AS, Khoo TL, Dorai AA. Dried irradiated human amniotic membrane as a biological dressing for facial burns--a 7-year case series. Burns. 2010 Sep;36(6):876-82. doi: 10.1016/j.burns.2009.07.001. Epub 2010 Mar 16.</citation>
    <PMID>20236771</PMID>
  </reference>
  <reference>
    <citation>Subach BR, Copay AG. The use of a dehydrated amnion/chorion membrane allograft in patients who subsequently undergo reexploration after posterior lumbar instrumentation. Adv Orthop. 2015;2015:501202. doi: 10.1155/2015/501202. Epub 2015 Jan 13.</citation>
    <PMID>25653880</PMID>
  </reference>
  <reference>
    <citation>Kurd SK, Hoffstad OJ, Bilker WB, Margolis DJ. Evaluation of the use of prognostic information for the care of individuals with venous leg ulcers or diabetic neuropathic foot ulcers. Wound Repair Regen. 2009 May-Jun;17(3):318-25. doi: 10.1111/j.1524-475X.2009.00487.x.</citation>
    <PMID>19660039</PMID>
  </reference>
  <reference>
    <citation>Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK, Gottrup F, Gurtner GC, Longaker MT. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 2009 Nov-Dec;17(6):763-71. doi: 10.1111/j.1524-475X.2009.00543.x.</citation>
    <PMID>19903300</PMID>
  </reference>
  <reference>
    <citation>Cherry DK, Hing E, Woodwell DA, Rechtsteiner EA. National Ambulatory Medical Care Survey: 2006 summary. Natl Health Stat Report. 2008 Aug 6;(3):1-39.</citation>
    <PMID>18972720</PMID>
  </reference>
  <reference>
    <citation>Pitts SR, Niska RW, Xu J, Burt CW. National Hospital Ambulatory Medical Care Survey: 2006 emergency department summary. Natl Health Stat Report. 2008 Aug 6;(7):1-38.</citation>
    <PMID>18958996</PMID>
  </reference>
  <reference>
    <citation>Miller SF, Bessey P, Lentz CW, Jeng JC, Schurr M, Browning S; ABA NBR Committee. National burn repository 2007 report: a synopsis of the 2007 call for data. J Burn Care Res. 2008 Nov-Dec;29(6):862-70; discussion 871. doi: 10.1097/BCR.0b013e31818cb046.</citation>
    <PMID>18997556</PMID>
  </reference>
  <reference>
    <citation>Cutting KF, Harding KG. Criteria for identifying wound infection. J Wound Care. 1994 Jun 2;3(4):198-201.</citation>
    <PMID>27922298</PMID>
  </reference>
  <reference>
    <citation>Baryza MJ, Baryza GA. The Vancouver Scar Scale: an administration tool and its interrater reliability. J Burn Care Rehabil. 1995 Sep-Oct;16(5):535-8.</citation>
    <PMID>8537427</PMID>
  </reference>
  <reference>
    <citation>Molnar JA, Lew WK, Rapp DA, Gordon ES, Voignier D, Rushing S, Willner W. Use of standardized, quantitative digital photography in a multicenter Web-based study. Eplasty. 2009;9:e4. Epub 2009 Jan 12.</citation>
    <PMID>19212431</PMID>
  </reference>
  <reference>
    <citation>Dornseifer U, Lonic D, Gerstung TI, Herter F, Fichter AM, Holm C, Schuster T, Ninkovic M. The ideal split-thickness skin graft donor-site dressing: a clinical comparative trial of a modified polyurethane dressing and aquacel. Plast Reconstr Surg. 2011 Oct;128(4):918-24. doi: 10.1097/PRS.0b013e3182268c02.</citation>
    <PMID>21681125</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 21, 2018</study_first_submitted>
  <study_first_submitted_qc>November 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human amnion membrane</keyword>
  <keyword>Autologous skin graft</keyword>
  <keyword>Scar Formation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

